Search

Displaying results 2371 - 2380 of 10000 in total
  1. Drug

    Bromhexine

    go.drugbank.com/drugs/DB09019
    ApprovedInvestigational

    It was introduced into the market in 1963, and is widely available as an over-the-counter drug in many countries. … It is derived from the Adhatoda vasica plant and aids in the clearance of excess mucus, improving breathing and reducing cough.

    Mixtures: GLICERTOX N FSynonyms: N-cyclohexyl-N-methyl-(2-amino-3,5-dibrombenzyl)amine, 3,5-dibromo-N(alpha)-cyclohexyl-N(alpha)-methyltoluene-alpha-2-diamine
  2. Drug

    Hydrocodone

    go.drugbank.com/drugs/DB00956
    ApprovedIllicitInvestigational

    Hydrocodone is a synthetic opioid derivative of codeine.[T116] It is commonly used in combination with [acetaminophen] to control moderate to severe pain. … Hydrocodone's more potent metabolite, [hydromorphone] has also found wide use as an analgesic and is frequently used in cases of severe pain.

  3. Drug

    Zenocutuzumab

    go.drugbank.com/drugs/DB15559
    ApprovedInvestigational

    [L51983] In May 2026, zenocutuzumab was granted additional approval by the US FDA for use in NRG1-positive cholangiocarcinoma. … [A264833,A264843] Zenocutuzumab is also capable of promoting antibody-dependent cellular cytotoxicity in cancer cells.

  4. Drug

    Norgestimate

    go.drugbank.com/drugs/DB00957
    ApprovedInvestigational

    Norgestimate was first described in the literature in 1977. … [A191068] It is commonly formulated with [ethinylestradiol] as a combined oral contraceptive that can also be used to treat moderate acne vulgaris.

    Synonyms: (17α)-17-(Acetyloxy)-13-ethyl-18,19-dinorpregn-4-en-20-yn-3-one 3-oxime, (+)-13-Ethyl-17-hydroxy-18,19-dinor-17α-pregn-4-en-20-yn-3-one oxime acetate (ester)
  5. Drug

    Ubrogepant

    go.drugbank.com/drugs/DB15328
    ApprovedInvestigational

    Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults. … [A189195] The development of oral gepants, including ubrogepant, may therefore constitute a significant advance in migraine headache treatment and may become the new standard of therapy in the treatment

  6. Drug

    Vutrisiran

    go.drugbank.com/drugs/DB16699
    ApprovedInvestigational

    [A249010] The Val30Met variant is the most prevalent among hereditary ATTR patients with polyneuropathy, especially in Portugal, France, Sweden, and Japan. … [L42085] Another siRNA indicated for the treatment of polyneuropathy associated with hereditary ATTR is [patisiran].[A249010] Vutrisiran was approved by the FDA in June 2022.

  7. Drug

    Pefloxacin

    go.drugbank.com/drugs/DB00487
    Approved

    A synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and gram-positive bacteria.

    Categories: Topoisomerase II Inhibitors
  8. Drug

    Metrizoic acid

    go.drugbank.com/drugs/DB09346
    Approved

    In general, the drug was well tolerated by patients during cardiac examinations [A32091]. … One study in 1976 demonstrated that metrizoic acid, when used for cardiac angiography, was well tolerated.

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    Atoltivimab

    go.drugbank.com/drugs/DB15898
    ApprovedInvestigational

    (i.e. through Fc-mediated immune effector function) antibody effects to play a role in combatting EBOV infection. … [A221825, A221830] A recent large-scale study elucidated that both neutralizing and Fc-mediated functions of antibodies were important for therapeutic benefit in animal models of EBOV infection.

  10. Drug

    Tiratricol

    go.drugbank.com/drugs/DB03604
    ApprovedInvestigational

    [A274073] Tiratricol is currently being investigated in US clinical trials. … [L53383] It was first approved by the EMA on February 12, 2025 for the treatment of peripheral thyrotoxicosis in patients with monocarboxylate transporter 8 (MCT8) deficiency,[A274038] a disorder characterized